PMID- 9548415
OWN - NLM
STAT- MEDLINE
DCOM- 19980428
LR  - 20190909
IS  - 0902-4441 (Print)
IS  - 0902-4441 (Linking)
VI  - 60
IP  - 3
DP  - 1998 Mar
TI  - Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for 
      Hodgkin's disease: a prospective study.
PG  - 166-71
AB  - This study presents the results of a prospective study of methyl-gag, ifosfamide, 
      methotrexate and etoposide (MIME) as salvage regimen for Hodgkin's disease (HD) 
      in Sweden. Sixty-four patients with recurrent or refractory HD were treated with 
      MIME between July 1988 and December 1993. All patients except one had, earlier, 
      been treated with and failed consecutive or alternating MOPP and ABVD. Median age 
      was 37 yr (range 14-73). Twenty patients (31%) achieved a complete remission (CR) 
      and 17 (27%) a partial remission (PR), giving an overall response rate of 58%. 
      The 5-yr survival for all patients was 43%. In a multivariate analysis, the most 
      important factors predicting a poor survival were the presence of extranodal 
      disease at relapse, male gender and high age. Twenty-nine patients were treated 
      with high-dose chemotherapy with stem-cell rescue after MIME. Those patients had 
      a similar survival compared to the patients responding to MIME but not treated 
      with high-dose chemotherapy. We conclude that MIME induces remissions in a high 
      proportion of patients with recurrent and refractory HD with acceptable toxicity. 
      The remissions probably need consolidation, but the nature of this consolidation 
      is still controversial.
FAU - Enblad, G
AU  - Enblad G
AD  - Department of Oncology, Uppsala University Hospital, Sweden. 
      Gunilla.Enblad@onkologi.uu.se
FAU - Hagberg, H
AU  - Hagberg H
FAU - Gustavsson, A
AU  - Gustavsson A
FAU - Glimelius, B
AU  - Glimelius B
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - OD5Q0L447W (Mitoguazone)
RN  - UM20QQM95Y (Ifosfamide)
RN  - YL5FZ2Y5U1 (Methotrexate)
RN  - MIME protocol
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Etoposide/administration & dosage
MH  - Female
MH  - Hodgkin Disease/complications/*drug therapy/mortality
MH  - Humans
MH  - Ifosfamide/administration & dosage
MH  - Male
MH  - Methotrexate/administration & dosage
MH  - Middle Aged
MH  - Mitoguazone/administration & dosage
MH  - Neoplasms, Second Primary/etiology
MH  - Prospective Studies
MH  - *Salvage Therapy
MH  - Survival Analysis
EDAT- 1998/04/21 00:00
MHDA- 1998/04/21 00:01
CRDT- 1998/04/21 00:00
PHST- 1998/04/21 00:00 [pubmed]
PHST- 1998/04/21 00:01 [medline]
PHST- 1998/04/21 00:00 [entrez]
AID - 10.1111/j.1600-0609.1998.tb01018.x [doi]
PST - ppublish
SO  - Eur J Haematol. 1998 Mar;60(3):166-71. doi: 10.1111/j.1600-0609.1998.tb01018.x.